Janet Woodcock, director of the Center for Drug Evaluation and Research (AP Images)
Government gears for unprecedented challenge of Eli Lilly antibody rollout as efficacy questions linger
After months of anticipation, the FDA has authorized the first antibody treatment for Covid-19. Now what?
The US government faces a challenge unlike virtually any it has faced during or before the pandemic. They will have to distribute scarce quantities of a much-sought drug throughout the country at a time when cases are reaching record levels, overburdening hospitals to the point where, in North Dakota, Covid-19 positive nurses have been authorized to continue working.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters